文献速递肝胆胰外科

微创与开放远端胰腺切除术治疗导管腺癌:泛欧倾向评分匹配研究

Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study.
PubMed 文献 · Ann Surg · 2019-01-01

该泛欧倾向评分匹配研究比较微创远端胰腺切除术(MIDP)与开放远端胰腺切除术(ODP)治疗胰腺导管腺癌(PDAC)的肿瘤学结局。共纳入1212例患者,MIDP组340例与ODP组1:1匹配。结果显示两组生存期相当,但MIDP的R0切除率更高,而Gerota筋膜切除率和淋巴结检出数更低。

要点

  • MIDP与ODP治疗PDAC的总生存期相当,中位OS分别为28个月和31个月(P=0.929)。
  • MIDP的R0切除率高于ODP(67% vs 58%,P=0.019),但Gerota筋膜切除率更低(31% vs 60%,P<0.001)。
  • MIDP的淋巴结检出数少于ODP(中位14枚 vs 22枚,P<0.001),提示需随机试验确认肿瘤学安全性。

核心结论

  • MIDP与ODP治疗PDAC的生存期相当,但R0切除率、Gerota筋膜切除率和淋巴结检出数的相反差异提示需随机试验确认MIDP的肿瘤学安全性。

研究设计与样本

  • 泛欧倾向评分匹配研究,纳入2007年1月1日至2015年7月1日期间接受MIDP(腹腔镜或机器人辅助)或ODP的PDAC患者,MIDP与ODP按1:1匹配。
  • 共纳入来自11个国家34个中心的1212例患者,其中356例(29%)接受MIDP,340例成功匹配。

主要发现

  • 匹配后MIDP中转率为19%(n=62)。
  • MIDP的中位出血量低于ODP[200 mL(60-400) vs 300 mL(150-500),P=0.001],中位住院时间更短[8(6-12)天 vs 9(7-14)天,P<0.001]。
  • MIDP与ODP的Clavien-Dindo≥3级并发症(18% vs 21%,P=0.431)和90天死亡率(2% vs 3%,P>0.99)相当。
  • MIDP的R0切除率更高(67% vs 58%,P=0.019),但Gerota筋膜切除率更低(31% vs 60%,P<0.001),淋巴结检出数更少[14(8-22) vs 22(14-31),P<0.001]。
  • MIDP与ODP的中位总生存期分别为28个月(95%CI 22-34)和31个月(95%CI 26-36),P=0.929。

临床怎么用

  • MIDP可考虑用于PDAC的远端胰腺切除术,但需注意其Gerota筋膜切除率和淋巴结检出数较低,可能影响肿瘤学根治性。
  • 鉴于R0切除率与淋巴结检出数的相反差异,应等待随机试验结果后再广泛推广MIDP用于PDAC。

局限性

  • 为倾向评分匹配的回顾性研究,可能存在未测量的混杂因素。
  • MIDP组中转率较高(19%),可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to compare oncological outcomes after minimally invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) in patients with pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Cohort studies have suggested superior short-term outcomes of MIDP vs. ODP. Recent international surveys, however, revealed that surgeons have concerns about the oncological outcomes of MIDP for PDAC. METHODS: This is a pan-European propensity score matched study including patients who underwent MIDP (laparoscopic or robot-assisted) or ODP for PDAC between January 1, 2007 and July 1, 2015. MIDP patients were matched to ODP patients in a 1:1 ratio. Main outcomes were radical (R0) resection, lymph node retrieval, and survival. RESULTS: In total, 1212 patients were included from 34 centers in 11 countries. Of 356 (29%) MIDP patients, 340 could be matched. After matching, the MIDP conversion rate was 19% (n = 62). Median blood loss [200 mL (60-400) vs 300 mL (150-500), P = 0.001] and hospital stay [8 (6-12) vs 9 (7-14) days, P < 0.001] were lower after MIDP. Clavien-Dindo grade ≥3 complications (18% vs 21%, P = 0.431) and 90-day mortality (2% vs 3%, P > 0.99) were comparable for MIDP and ODP, respectively. R0 resection rate was higher (67% vs 58%, P = 0.019), whereas Gerota's fascia resection (31% vs 60%, P < 0.001) and lymph node retrieval [14 (8-22) vs 22 (14-31), P < 0.001] were lower after MIDP. Median overall survival was 28 [95% confidence interval (CI), 22-34] versus 31 (95% CI, 26-36) months (P = 0.929). CONCLUSIONS: Comparable survival was seen after MIDP and ODP for PDAC, but the opposing differences in R0 resection rate, resection of Gerota's fascia, and lymph node retrieval strengthen the need for a randomized trial to confirm the oncological safety of MIDP.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. van Hilst J, de Rooij T, Klompmaker S, et al. Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study. Ann Surg. 2019. PMID: 29099399. doi:10.1097/SLA.0000000000002561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。